Avadel, Lumryz
Avadel Gets Expanded FDA OK of Lumryz for Use in Children
Avadel Pharmaceuticals has won expanded Food and Drug Administration approval of its narcolepsy drug Lumryz for use in children. Avadel on Thursday said the FDA nod covers Lumryz for the treatment of cataplexy, or excessive daytime sleepiness, in children ages seven and older with narcolepsy, a chronic sleep disorder.
The U.S. Food and Drug Administration has approved Avadel Pharmaceuticals' sleep disorder drug for children aged 7 years and ...
Avadel Pharmaceuticals said its once-nightly narcolepsy drug Lumryz can now be used to treat children older than 7 years of ...
Shares of Jazz Pharmaceuticals are trading only slightly higher in the last few weeks despite two unexpected wins. Explore ...
Hosted on MSN7mon
Avadel surges after royalty rate awarded to Jazz in patent dispute lower than requested (update)Updare 3:55pm: Adds Avadel comment. Avadel Pharmaceuticasl (NASDAQ:AVDL) jumped 18% after a jury ruled in favor of Jazz Pharmaceuticals (NASDAQ:JAZZ) in a patent dispute over a sleep disorder drug ...
Cetera Investment Advisers trimmed its position in Avadel Pharmaceuticals plc (NASDAQ:AVDL – Free Report) by 5.4% during the second quarter, according to the company in its most recent 13F filing with ...
(RTTNews) - Avadel Pharmaceuticals plc (AVDL), Tuesday revealed that 94 percent of patients in RESTORE study with narcolepsy preferred the once-nightly regimen of Lumryz over twice-nightly Oxybate ...
Avadel Pharmaceuticals plc (NASDAQ: AVDL) reported better-than-expected fourth-quarter revenue results and also issued a corporate update on Monday.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback